Spirocyclic sulfamides as beta-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney, M.A., Barreiro, G., Ogilvie, K., Hajos-Korcsok, E., Murray, J., Vajdos, F., Ambroise, C., Christoffersen, C., Fisher, K., Lanyon, L., Liu, J., Nolan, C.E., Withka, J.M., Borzilleri, K.A., Efremov, I., Oborski, C.E., Varghese, A., O'Neill, B.T.(2012) J Med Chem 55: 9224-9239
- PubMed: 22984865 
- DOI: 10.1021/jm3009426
- Primary Citation of Related Structures:  
4FM7, 4FM8 - PubMed Abstract: 
β-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD). Herein, we describe the discovery of a novel class of BACE-1 inhibitors represented by sulfamide 14g, using a medicinal chemistry ...